Corbus Pharmaceuticals Holdings, Inc. Income Statement
CRBP|8 years of annual SEC 10-K data (FY2015-FY2022)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Corbus Pharmaceuticals Holdings, Inc. reported $881,705 in revenue and $46M in net loss for FY2022. Revenue has grown at a 4.5% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $881.7K | $3.9M | $36.1M | $4.8M | $2.4M | $648.4K | $648.4K | $648.4K |
| SG&A Expense | $20.4M | $28.5M | $23.6M | $13.0M | $9.0M | $3.6M | $3.6M | $1.4M |
| R&D Expense | $36.4M | $98.3M | $89.6M | $48.6M | $26.0M | $5.9M | $5.9M | $1.3M |
| Operating Income | -$56.0M | -$122.8M | -$77.1M | -$56.7M | -$32.6M | -$8.9M | -$8.9M | -$2.6M |
| Interest Expense | $2.7M | $1.1M | $0 | - | - | $2.4K | $2.4K | $24.0K |
| Net Income | -$45.6M | -$111.3M | -$71.5M | -$55.7M | -$32.4M | -$8.9M | -$8.9M | -$2.5M |
| EPS (Basic) | -$11.15 | -$1.42 | - | - | - | - | - | - |
| EPS (Diluted) | -$11.15 | -$1.42 | -$1.12 | -$0.98 | -$0.65 | -$0.28 | -$0.28 | -$0.13 |
| Shares Outstanding | 4.2M | 98.9M | 64.7M | 57.2M | 55.6M | 37.6M | 37.6M | 25.9M |
| Operating Margin | -6350.1% | -3119.2% | -213.3% | -1176.8% | -1334.4% | -1365.5% | -1365.5% | -408.3% |
| Profit Margin | -5176.4% | -2826.1% | -197.7% | -1154.5% | -1328.7% | -1365.0% | -1365.0% | -391.8% |